Coronavirus

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

With its latest earnings report showing the financial impact of the vaccine, the Delta variant becoming the dominant strain in the US, and concerns of waning immunity, the company believes there is evidence for an additional booster shot.

A new report based on wearable technology finds it takes an average of 79 days for patients’ resting heart rates to return to normal following COVID-19 infection.

Commonly reported issues included delirium, encephalopathies and psychiatric complications.

Public information campaigns may potentially boost rates of vaccination.

As much as 2% of vaccine recipients have reported anaphylaxis following their first shot.

Asymptomatic and symptomatic COVID-19 cases among health care personnel were reduced after vaccination despite surge in infected patients.

The agency is expected to make a statement later today on masking recommendations.

The nasal mucosa was seen to be an essential determinant of overall disease trajectory.

The framework could help officials assess the true burden of disease in certain areas.

Use of remdesivir for COVID-19 was associated with longer hospital stays but was not associated with improved mortality, a recent study of 2344 patients at 123 VA hospitals found.

Modeling showed 1 in 4 infected people pass the infection to a family member.

Pfizer and Moderna will include children aged 5-11 years old in ongoing trials to speak toward risk of rare adverse events observed in other young recipients.

The statement includes over 50 societies and organizations, representing millions of workers.

Communities experiencing such health inequity and disparities are more likely to have mistrust in systems that have continuously failed them. Understanding the perspectives of those disproportionately affected is critical to not only address them, but also work to correct and prevent these disparities moving forward.

Not much is known about the relationship between the expression and activity of SPM pathways and COVID-19 disease severity.

The lineage C.37, (Lambda variant), was recently classified as a variant of interest by the World Health Organization (WHO) based on its high circulation rates in South America, and has showed "the ability to escape from neutralizing antibodies elicited by CoronaVac."

Associations found in people under the age of 45 were weaker in patients over that age.

Patients with a history of malnutrition had higher odds of developing severe disease.

A new report, based on data from dialysis centers, suggests the US is far from reaching so-called “herd immunity.”

While a significantly reduced effectiveness was seen with 1 dose, only a small reduction was observed after 2.

Virtual support services were crucial for providing continued care and education.

PLWH should strictly maintain ART therapy and COVID-19 mitigation efforts.

A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.

The designation moves the companies' PDUFA date up to January 2022, when BNT162b2 may become the first regulated COVID-19 vaccine.

94% of the participants developed IgG antibodies against the virus 3 weeks after administration.

Truncated ACE2 levels served to discriminate patients infected with SARS-CoV-2 and influenza A.

A large study finds 1 out of 2 patients develop at least one during their hospital stay.

The Johnson & Johnson vaccine showed neutralizing antibody responses against variants of concern.

Life expectancy for Black and Hispanic Americans dropped 2 to 3 times more than that of White Americans during the pandemic, a research letter in JAMA Network Open said.